| Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group Lancet (London, England) 397 (10285), 1637, 2021 | 2065* | 2021 |
| British Thoracic Society guideline for diagnostic flexible bronchoscopy in adults: accredited by NICE IA Du Rand, J Blaikley, R Booton, N Chaudhuri, V Gupta, S Khalid, ... Thorax 68 (Suppl 1), i1-i44, 2013 | 916 | 2013 |
| Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study RA Evans, H McAuley, EM Harrison, A Shikotra, A Singapuri, M Sereno, ... The Lancet Respiratory Medicine 9 (11), 1275-1287, 2021 | 512 | 2021 |
| Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group, PW Horby, M Mafham, L Peto, ... Medrxiv, 2021.06. 15.21258542, 2021 | 495* | 2021 |
| Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised … AU Wells, KR Flaherty, KK Brown, Y Inoue, A Devaraj, L Richeldi, T Moua, ... The lancet Respiratory medicine 8 (5), 453-460, 2020 | 453 | 2020 |
| Idiopathic pulmonary fibrosis (IPF): an overview SL Barratt, A Creamer, C Hayton, N Chaudhuri Journal of clinical medicine 7 (8), 201, 2018 | 340 | 2018 |
| Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study RA Evans, OC Leavy, M Richardson, O Elneima, HJC McAuley, ... The Lancet Respiratory Medicine 10 (8), 761-775, 2022 | 319 | 2022 |
| Drug-induced interstitial lung disease: a systematic review S Skeoch, N Weatherley, AJ Swift, A Oldroyd, C Johns, C Hayton, A Giollo, ... Journal of clinical medicine 7 (10), 356, 2018 | 306 | 2018 |
| Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis O Abani, A Abbas, F Abbas, J Abbas, K Abbas, M Abbas, S Abbasi, ... The Lancet 400 (10349), 359-368, 2022 | 239 | 2022 |
| The therapy of idiopathic pulmonary fibrosis: what is next? V Somogyi, N Chaudhuri, SE Torrisi, N Kahn, V Müller, M Kreuter European Respiratory Review 28 (153), 2019 | 238 | 2019 |
| Outcome of hospitalization for COVID-19 in patients with interstitial lung disease. An international multicenter study TM Drake, AB Docherty, EM Harrison, JK Quint, H Adamali, S Agnew, ... American journal of respiratory and critical care medicine 202 (12), 1656-1665, 2020 | 224 | 2020 |
| Real world experiences: pirfenidone and nintedanib are effective and well tolerated treatments for idiopathic pulmonary fibrosis G Hughes, H Toellner, H Morris, C Leonard, N Chaudhuri Journal of clinical medicine 5 (9), 78, 2016 | 178 | 2016 |
| Association of cardiovascular disease with respiratory disease P Carter, J Lagan, C Fortune, DL Bhatt, J Vestbo, R Niven, N Chaudhuri, ... Journal of the American College of Cardiology 73 (17), 2166-2177, 2019 | 173 | 2019 |
| Persistent self-reported changes in hearing and tinnitus in post-hospitalisation COVID-19 cases KJ Munro, K Uus, I Almufarrij, N Chaudhuri, V Yioe International journal of audiology 59 (12), 889-890, 2020 | 123 | 2020 |
| Toll-like receptors and chronic lung disease N Chaudhuri, SK Dower, MKB Whyte, I Sabroe Clinical science 109 (2), 125-133, 2005 | 115 | 2005 |
| Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy … TM Maher, VA Tudor, P Saunders, MA Gibbons, SV Fletcher, CP Denton, ... The Lancet Respiratory Medicine 11 (1), 45-54, 2023 | 114 | 2023 |
| Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled … JJ Solomon, SK Danoff, FA Woodhead, S Hurwitz, R Maurer, I Glaspole, ... The Lancet Respiratory Medicine 11 (1), 87-96, 2023 | 96 | 2023 |
| Acute exacerbation of idiopathic pulmonary fibrosis: international survey and call for harmonisation M Kreuter, M Polke, SLF Walsh, J Krisam, HR Collard, N Chaudhuri, ... European respiratory journal 55 (4), 2020 | 92 | 2020 |
| Summary of the British Thoracic Society guideline for diagnostic flexible bronchoscopy in adults IA Du Rand, J Blaikley, R Booton, N Chaudhuri, V Gupta, S Khalid, ... Thorax 68 (8), 786-787, 2013 | 82 | 2013 |
| Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study TM Maher, S Stowasser, Y Nishioka, ES White, V Cottin, I Noth, M Selman, ... The Lancet respiratory medicine 7 (9), 771-779, 2019 | 79 | 2019 |
Conal HaytonHonorary Senior Lecturer in Respiratory Medicine, University of Manchester在 manchester.ac.uk 的电子邮件经过验证
